Traumatic Brain Injury Biomarkers Market Report 2025

The traumatic brain injury biomarkers market size has grown exponentially in recent years. It will grow from $1.13 billion in 2024 to $1.38 billion in 2025 at a compound annual growth rate (CAGR) of 22.1%. The growth in the historic period can be attributed to the rising incidence of road traffic accidents, increasing awareness of brain health, growth in emergency room visits, an increase in military-related traumatic brain injury cases, and the expansion of diagnostic options.

The traumatic brain injury biomarkers market size is expected to see exponential growth in the next few years. It will grow to $3.03 billion in 2029 at a compound annual growth rate (CAGR) of 21.7%. The growth in the forecast period can be attributed to increasing demand for rapid diagnostic tools, growing investments in neurological research, rising adoption of personalized medicine, expansion of clinical trials for brain injury biomarkers, and higher healthcare expenditure. Major trends in the forecast period include advancements in proteomic platforms, innovations in blood-based biomarker detection, development of portable diagnostic devices, research in neuroinflammation markers, and the integration of artificial intelligence in biomarker analysis.

The rising number of road traffic accidents is expected to drive growth in the traumatic brain injury biomarkers market in the coming years. Road traffic accidents are unplanned events that cause injury, harm, or damage, often necessitating immediate medical intervention. The increase in such accidents is largely due to higher private vehicle usage associated with urbanization and motorization. Traumatic brain injury biomarkers support care in these situations by enabling rapid and accurate assessment of head injuries. By detecting specific proteins in the blood, these biomarkers allow clinicians to make timely treatment decisions, improving patient outcomes in emergency settings. For example, according to a May 2024 report on road safety by the European Commission, the total number of road fatalities in the EU reached 20,634 in 2022, up from 19,917 in 2021. Therefore, the growing number of road traffic accidents is fueling the market for traumatic brain injury biomarkers.

The increasing adoption of personalized medicine is also expected to support growth in the traumatic brain injury biomarkers market. Personalized medicine involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize care and outcomes. The demand for this approach is rising due to advancements in genomic technologies, which allow precise identification of genetic variations and enable targeted therapies. Traumatic brain injury biomarkers contribute to personalized medicine by identifying specific biological indicators associated with brain injuries. They help design individualized treatment plans based on a patient’s unique response, enhancing recovery outcomes and optimizing clinical decision-making. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, up from 12 in 2022. Hence, the growing adoption of personalized medicine is driving the market for traumatic brain injury biomarkers.

Key players in the traumatic brain injury biomarkers market are developing innovative solutions, such as lab-based blood tests, to enhance the speed and accuracy of concussion diagnosis. A lab-based blood test measures specific biomarkers in the blood to assess the presence and severity of brain injuries, enabling earlier and more objective clinical decisions. For example, in June 2025, Abbott Laboratories, a US-based healthcare company, launched the Alinity i and Architect i1000SR lab tests. These tests measure two key biomarkers glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase (UCH)-L1 to help clinicians evaluate suspected concussions within 12 hours of injury. The tests deliver results in just 18 minutes, supporting faster triage decisions in emergency settings and reducing the need for unnecessary CT scans. This innovation provides physicians with a reliable tool for identifying patients with potential traumatic brain injuries and represents a major advancement in providing rapid, evidence-based care in emergency departments.

Major players in the traumatic brain injury biomarkers market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Biogen Inc., BioMérieux S.A., DiaSorin S.p.A., Abcam Limited, Fujirebio Inc., Meso Scale Diagnostics (MSD), Olink Holding AB, Quanterix Corporation, OriGene Technologies Inc., BioDirection Inc., NanoDx Inc., BrainScope Company Inc., BrainBox Solutions Inc., DiaGenic ASA, NeuroTrauma Sciences LLC, and Banyan Biomarkers Inc.

North America was the largest region in the traumatic brain injury biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in traumatic brain injury biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the traumatic brain injury biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Traumatic brain injury (TBI) biomarkers are measurable biological indicators, including proteins, enzymes, or genetic material, present in blood, cerebrospinal fluid, or brain tissue that indicate the occurrence and severity of brain injury. These biomarkers are used to detect, diagnose, and monitor TBI, providing insights into injury extent and informing treatment decisions.

The primary categories of TBI biomarkers include protein biomarkers, genetic biomarkers, and metabolomic biomarkers. Protein biomarkers are specific proteins released into blood or cerebrospinal fluid due to brain tissue damage and can be measured to evaluate the presence, severity, and progression of the injury. Biomarkers can be collected from samples such as blood, cerebrospinal fluid (CSF), and urine, and are applied in diagnosis, prognosis, and monitoring treatment response. Key end users include hospitals and clinics, diagnostic laboratories, and research institutes.

The traumatic brain injury biomarkers market research report is one of a series of new reports that provides traumatic brain injury biomarkers market statistics, including the traumatic brain injury biomarkers industry global market size, regional shares, competitors with the traumatic brain injury biomarkers market share, detailed traumatic brain injury biomarkers market segments, market trends, and opportunities, and any further data you may need to thrive in the traumatic brain injury biomarkers industry. This traumatic brain injury biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The traumatic brain injury biomarkers market consists of revenues earned by entities by providing services such as biomarker validation studies, clinical trial support, neurological data analysis, biomarker-based screening programs, and regulatory consulting. The market value includes the value of related goods sold by the service provider or included within the service offering. The traumatic brain injury biomarkers market also includes sales of biomarker assay kits, lab-on-a-chip devices, neuroimaging-linked biomarkers, biosensor-integrated test systems, and multiplex diagnostic platforms. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.